secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0000886163-25-000008
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand Q4 revenue up 52% to $42.8M; core adj EPS $1.27; reaffirms 2025 guidance
-------------------------------------------------------------------------------

- Q4 total rev $42.8M (+52% YoY); royalties $34.8M (+55%) driven by Qarziba and Filspari.
- Core adjusted net income from cont ops $25.2M ($1.27/diluted) vs $18.6M ($1.05) prior year.
- Full year adj net income $156.0M ($8.25/diluted); core adj $108.5M ($5.74/diluted).
- Reaffirms 2025 guidance: total rev $180-200M, adjusted EPS $6.00-$6.25.
- Closed $50M royalty investment in Castle Creek Biosciences for D-Fi Phase 3 study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616325000008/0000886163-25-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616325000008/lgnd-20250227.htm
  HTML page:      https://secwatch.observer/filing/0000886163-25-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer